Management of Menorrhagia

First-Line Treatment Recommendation

• The American College of Obstetricians and Gynecologists recommends the levonorgestrel-releasing intrauterine system (LNG-IUS) as the most effective first-line treatment for menorrhagia, reducing menstrual blood loss by up to 96% after 12 months and resulting in amenorrhea or oligomenorrhea in approximately 50% of users after 2 years 1

Treatment Algorithm by Clinical Context

When Contraception is Desired or Acceptable

• Combined oral contraceptives are an effective alternative to LNG-IUS, regularizing cycles and reducing bleeding, with a significant reduction in blood loss compared to NSAIDs, antifibrinolytics, or oral progestins 1, 2

When Contraception is Not Desired or Hormonal Therapy is Contraindicated

• Tranexamic acid (1.5-2g three times daily during menstruation) is the first-line non-hormonal option, reducing menstrual blood loss by 34-59% over 2-3 cycles, and is particularly effective in women with bleeding disorders or coagulopathies 1

Essential Diagnostic Evaluation

Mandatory Initial Testing

• The American College of Obstetricians and Gynecologists recommends screening for iron deficiency anemia, as menorrhagia is the most common cause of iron deficiency in women of reproductive age, affecting 20-25% of this population 1

Anemia Management

• Supplement with ferrous sulfate 200mg three times daily to correct anemia and replenish iron stores, and continue treatment for three months after correction of anemia to replenish iron stores 1

Surgical Options When Medical Management Fails

Minimally Invasive Procedures

• Endometrial ablation is appropriate for women who have completed childbearing, with satisfaction rates exceeding 95%, and uterine artery embolization (UAE) has an 81-100% clinical success rate, with symptom improvement in 83% of women at 3 months 1, 2

Follow-Up Protocol

• Re-evaluate at 3-6 months after initiating treatment to assess efficacy, and monitor hemoglobin and MCV every 3 months for 1 year, then annually 1

Common Pitfalls to Avoid

• Avoid prescribing progestins for more than 6 months due to meningioma risk 1, 2

Safety and Contraindications of Estradiol Valerate/Dienogest for Menorrhagia

Effectiveness of Combined Oral Contraceptives in Reducing Menstrual Bleeding

• Combined oral contraceptives, including estradiol valerate/dienogest, are effective for regularizing menstrual cycles and reducing heavy bleeding in reproductive‑age women. Evidence level not specified. [3] [4]

Screening and Contraindications (WHO Medical Eligibility Criteria)

• Prior to prescribing estradiol valerate/dienogest, clinicians should screen for standard combined oral‑contraceptive contraindications per the WHO Medical Eligibility Criteria—specifically a history of thromboembolism, stroke, cardiovascular disease, migraine with aura (at any age), and smoking in women aged ≥ 35 years. Evidence level not specified. [4] [5]

Pre‑prescription Assessment (American Academy of Dermatology)

• A thorough medical history and measurement of blood pressure are required before initiating therapy; routine Pap smear and pelvic examination are not mandatory. Evidence level not specified. 3

Pregnancy Exclusion and Contraceptive Counseling (European Society of Cardiology)

• Clinicians must confirm that the patient is not pregnant and provide comprehensive contraceptive counseling before starting estradiol valerate/dienogest. Evidence level not specified. 6